Sandbox Reserved 1167
From Proteopedia
(Difference between revisions)
Line 52: | Line 52: | ||
== Clinical Relevance == | == Clinical Relevance == | ||
- | Because of GCGR's role in glucose homeostasis, it is a potential drug target for Type 2 diabetes. Specifically, molecules that | + | Because of GCGR's role in glucose homeostasis, it is a potential drug target for [https://en.wikipedia.org/wiki/Diabetes_mellitus_type_2 Type 2 diabetes]. Specifically, molecules that antagonize the glucagon receptor may be able to lower blood sugar levels. Studies have shown that two antibodies, mAb1 and mAb23, target the ECD domain of the GCGR interrupt glucagon binding<ref>PMID:22908259</ref>. Disrupting the normal interactions between the ECD and the 7tm domains, these antibiotics inhibit the receptor's function and help to lower blood glucose level. Additional research has shown that another antibody, mAb7, inhibits GCGR allosterically<ref>PMID:24189067</ref>. Binding to a site outside of the binding pocket, mAb7 inhibits the receptor without interacting with essential glucagon binding residues. |
</StructureSection> | </StructureSection> |
Revision as of 14:46, 30 March 2016
This Sandbox is Reserved from Jan 11 through August 12, 2016 for use in the course CH462 Central Metabolism taught by R. Jeremy Johnson at the Butler University, Indianapolis, USA. This reservation includes Sandbox Reserved 1160 through Sandbox Reserved 1184. |
To get started:
More help: Help:Editing |
Class B Human Glucagon G-Protein Coupled Receptor
References
- ↑ Yang L, Yang D, de Graaf C, Moeller A, West GM, Dharmarajan V, Wang C, Siu FY, Song G, Reedtz-Runge S, Pascal BD, Wu B, Potter CS, Zhou H, Griffin PR, Carragher B, Yang H, Wang MW, Stevens RC, Jiang H. Conformational states of the full-length glucagon receptor. Nat Commun. 2015 Jul 31;6:7859. doi: 10.1038/ncomms8859. PMID:26227798 doi:http://dx.doi.org/10.1038/ncomms8859
- ↑ Lotfy M, Kalasz H, Szalai G, Singh J, Adeghate E. Recent Progress in the Use of Glucagon and Glucagon Receptor Antago-nists in the Treatment of Diabetes Mellitus. Open Med Chem J. 2014 Dec 31;8:28-35. doi: 10.2174/1874104501408010028., eCollection 2014. PMID:25674162 doi:http://dx.doi.org/10.2174/1874104501408010028
- ↑ Siu FY, He M, de Graaf C, Han GW, Yang D, Zhang Z, Zhou C, Xu Q, Wacker D, Joseph JS, Liu W, Lau J, Cherezov V, Katritch V, Wang MW, Stevens RC. Structure of the human glucagon class B G-protein-coupled receptor. Nature. 2013 Jul 25;499(7459):444-9. doi: 10.1038/nature12393. Epub 2013 Jul 17. PMID:23863937 doi:10.1038/nature12393
- ↑ Siu FY, He M, de Graaf C, Han GW, Yang D, Zhang Z, Zhou C, Xu Q, Wacker D, Joseph JS, Liu W, Lau J, Cherezov V, Katritch V, Wang MW, Stevens RC. Structure of the human glucagon class B G-protein-coupled receptor. Nature. 2013 Jul 25;499(7459):444-9. doi: 10.1038/nature12393. Epub 2013 Jul 17. PMID:23863937 doi:10.1038/nature12393
- ↑ Siu FY, He M, de Graaf C, Han GW, Yang D, Zhang Z, Zhou C, Xu Q, Wacker D, Joseph JS, Liu W, Lau J, Cherezov V, Katritch V, Wang MW, Stevens RC. Structure of the human glucagon class B G-protein-coupled receptor. Nature. 2013 Jul 25;499(7459):444-9. doi: 10.1038/nature12393. Epub 2013 Jul 17. PMID:23863937 doi:10.1038/nature12393
- ↑ Koth CM, Murray JM, Mukund S, Madjidi A, Minn A, Clarke HJ, Wong T, Chiang V, Luis E, Estevez A, Rondon J, Zhang Y, Hotzel I, Allan BB. Molecular basis for negative regulation of the glucagon receptor. Proc Natl Acad Sci U S A. 2012 Sep 4;109(36):14393-8. Epub 2012 Aug 20. PMID:22908259 doi:http://dx.doi.org/10.1073/pnas.1206734109
- ↑ Mukund S, Shang Y, Clarke HJ, Madjidi A, Corn JE, Kates L, Kolumam G, Chiang V, Luis E, Murray J, Zhang Y, Hotzel I, Koth CM, Allan BB. Inhibitory mechanism of an allosteric antibody targeting the glucagon receptor. J Biol Chem. 2013 Nov 4. PMID:24189067 doi:http://dx.doi.org/10.1074/jbc.M113.496984